Abstract
Presenting author: Theresa Junker, RN, PhD
Presenting author's affiliation Research and Innovation Unit of Radiology, Odense University Hospital
All authors and affiliation, including presenting author Junker, T. (1,2) Duus, L.A. (1) Nørgaard, B. (3) Azawi, N. (4,5) Rasmussen, B.S.B. (1,2) Lund, L. (6,2) Graumann, O. (1,2)
1: Research and Innovation Unit of Radiology, Odense University Hospital,
2: Department of Clinical Research, University of Southern Denmark
3: Department of Public Health, University of Southern Denmark
4: Department of Urology, Zealand University Hospital Roskilde
5: Department of Clinical Medicine, University of Copenhagen
6: Department of Urology, Odense University Hospital
Introduction
Partial nephrectomy (PN) is the gold standard for treating renal cell carcinoma (RCC) stage cT1.
However, alternative minimally invasive treatments, such as percutaneous cryoablation (PCA),
have been proposed to minimize the adverse effects on patient’s health-related quality of life
(HRQoL). We aimed to evaluate and compare the HRQoL of patients treated with PN or PCA for
RCC stage cT1 two years after treatment.
Materials & Methods
Patients treated with PN or PCA for RCC stage cT1 between 2019 and 2021 at two university
hospitals in Denmark were offered inclusion. Exclusion criteria: insufficient understanding of the
Danish language, cognitive deterioration, conversion to nephrectomy, or salvage procedures. The
EORCT QLQ C30 questionnaire was distributed before treatment and at one- and two-years post
treatment. A linear mixed-effect model was used to analyze changes from baseline to follow-up
between the groups.
Results
We included 168 patients (PN: 79; PCA: 89). The response rate was 100% at baseline and 88% and
74% after one and two years, respectively. Patients receiving PCA were significantly older (median
69.0 vs. 62.1 years), had a significantly higher score on the Charlson Comorbidity Index (3 vs. 2),
and were treated for significantly smaller tumors (3.06 vs. 3.75 cm) compared to PN. Patients
treated with PCA had lower baseline scores on physical (p < 0.001), role (p = 0.004), and social
functioning (p=0.044) compared to PN. A significant difference from baseline to one-year followup was
found for emotional functioning (p=0.006), favoring PCA over PN as the only HRQoL
scale. No significant changes from baseline to the two-year follow-up were found for any HRQoL
scales.
Conclusions
We found significant differences between baseline HRQoL between patients treated with PCA and
PN. However, no significant differences between the treatment groups were observed in any
HRQoL scales from baseline to two-year follow-up
Presenting author's affiliation Research and Innovation Unit of Radiology, Odense University Hospital
All authors and affiliation, including presenting author Junker, T. (1,2) Duus, L.A. (1) Nørgaard, B. (3) Azawi, N. (4,5) Rasmussen, B.S.B. (1,2) Lund, L. (6,2) Graumann, O. (1,2)
1: Research and Innovation Unit of Radiology, Odense University Hospital,
2: Department of Clinical Research, University of Southern Denmark
3: Department of Public Health, University of Southern Denmark
4: Department of Urology, Zealand University Hospital Roskilde
5: Department of Clinical Medicine, University of Copenhagen
6: Department of Urology, Odense University Hospital
Introduction
Partial nephrectomy (PN) is the gold standard for treating renal cell carcinoma (RCC) stage cT1.
However, alternative minimally invasive treatments, such as percutaneous cryoablation (PCA),
have been proposed to minimize the adverse effects on patient’s health-related quality of life
(HRQoL). We aimed to evaluate and compare the HRQoL of patients treated with PN or PCA for
RCC stage cT1 two years after treatment.
Materials & Methods
Patients treated with PN or PCA for RCC stage cT1 between 2019 and 2021 at two university
hospitals in Denmark were offered inclusion. Exclusion criteria: insufficient understanding of the
Danish language, cognitive deterioration, conversion to nephrectomy, or salvage procedures. The
EORCT QLQ C30 questionnaire was distributed before treatment and at one- and two-years post
treatment. A linear mixed-effect model was used to analyze changes from baseline to follow-up
between the groups.
Results
We included 168 patients (PN: 79; PCA: 89). The response rate was 100% at baseline and 88% and
74% after one and two years, respectively. Patients receiving PCA were significantly older (median
69.0 vs. 62.1 years), had a significantly higher score on the Charlson Comorbidity Index (3 vs. 2),
and were treated for significantly smaller tumors (3.06 vs. 3.75 cm) compared to PN. Patients
treated with PCA had lower baseline scores on physical (p < 0.001), role (p = 0.004), and social
functioning (p=0.044) compared to PN. A significant difference from baseline to one-year followup was
found for emotional functioning (p=0.006), favoring PCA over PN as the only HRQoL
scale. No significant changes from baseline to the two-year follow-up were found for any HRQoL
scales.
Conclusions
We found significant differences between baseline HRQoL between patients treated with PCA and
PN. However, no significant differences between the treatment groups were observed in any
HRQoL scales from baseline to two-year follow-up
| Originalsprog | Dansk |
|---|---|
| Publikationsdato | 31. aug. 2023 |
| Status | Udgivet - 31. aug. 2023 |
| Begivenhed | Danske Kræftforskningsdage - Danish Cancer Research Days 2023 - ODEON, Odense C, Danmark Varighed: 31. aug. 2023 → 1. sep. 2023 https://www.dccc.dk/siteassets/danske-kraftforskningsdage/2023/abstractbook/abstractbook_final_2023_vers2.pdf |
Konference
| Konference | Danske Kræftforskningsdage - Danish Cancer Research Days 2023 |
|---|---|
| Lokation | ODEON |
| Land/Område | Danmark |
| By | Odense C |
| Periode | 31/08/2023 → 01/09/2023 |
| Internetadresse |